Anti-Parkinson Drugs Global Market Report 2022 – By Drugs Class (Levodopa/Carbidopa, Dopamine Receptor Agonists, Monoamine Oxidase Type B (MAO-B) Inhibitors, Catechol-O-Methyltransferase (COMT)-inhibitors, Anticholinergics), By Route of Administration (Oral, Injection, Transdermal), By Distribution Channel (Hospital Pharmacies, Retailer Pharmacies, Online Pharmacies) – Market Size, Trends, And Global Forecast 2022-2026

Starting Price : $5000.00 | Pages : 175 | Published : March 2022 | SKU CODE : 7742 | Delivery Time: 2-3 business days | Format :


The anti-Parkinson drugs market consists of sales of drugs used for treating Parkinson's disease (PD), generated by the establishments that manufacture these drugs. Parkinson's disease is a neurodegenerative disorder that affects predominately dopaminergic neurons in a specific area of the brain named substantia nigra and disturbs the movement of the body. People suffering from PD may experience tremor, bradykinesia, limb rigidity, gait, and balance problems.

The main class of anti-Parkinson drugs are levodopa/carbidopa, dopamine receptor agonists, monoamine oxidase type b (MAO-b) inhibitors, catechol-o-methyltransferase (COMT)-inhibitors, anticholinergics and other drugs.catechol-O-methyltransferase (COMT) inhibitors are a class of drugs used to treat Parkinson's disease symptoms in conjunction with carbidopa-levodopa therapy. The main types of fertility drugs are prescription fertility drugs and over-the-counter fertility drugs. The drugs are administered through oral, injection, and transdermal that are distributed through hospital pharmacies, retail pharmacies and online pharmacies.

The global anti-Parkinsons drugs market size is expected to grow from $8.86 billion in 2021 to $9.56 billion in 2022 at a compound annual growth rate (CAGR) of 7.9%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The global anti-Parkinson drugs market size is expected to reach $12.25 billion in 2026 at a CAGR of 6.4%.

The increasing geriatric population and surging cases of Parkinson's disease (PD) are projected to drive the demand for the anti-Parkinson drugs market. PD commonly occurs in people over the age of 60 years. According to the United Nations Department of Economic and Social Affairs, one in 11 people in the world was over the age of 65 in 2019 and this number is expected to increase to one in six people by the end of 2050. Furthermore, according to the Michael J. Fox Foundation for Parkinson’s Research’s statistics published in June 2019, over 1 million Americans live with PD. Degeneration of neurons in the geriatric population and the surge in cases of Parkinson’s disease is therefore driving the market growth.

Increasing investments by governments and companies for Parkinson’s disease drug R&D is a major trend in the anti-Parkinson drugs market. For instance, according to the report published by the Parkinson’s Foundation, the foundation awarded $6 million to Parkinson's disease (PD) research. In January 2019, Parkinson’s UK Research and Support charity in the United Kingdom announced a research investment of $1.9 million (£1.5 million) into its drug discovery program to develop novel gene transcription modulators for Parkinson’s disease. Hence, increasing investments in Parkinson’s drug development are expected to drive the anti-Parkinson's drugs market.

The high cost of Parkinson’s disease treatment is anticipated to limit the growth of anti-Parkinson's drugs market over the forecast period. According to the Michael J. Fox Foundation for Parkinson’s Research’s statistics published in June 2019, the economic burden of Parkinson’s disease on patients, families, and the federal governments is increasing. In the United States, the overall cost of Parkinson’s disease to individuals, families, and government is $51.9 billion annually, with $25.4 billion on direct medical costs (including hospitalization and medication). Thus, the high cost of Parkinson's disease treatment is expected to impact the anti-Parkinson drugs market.

In June 2019, AbbVie Inc., a global research-driven biopharmaceutical company, announced the acquisition of Allergan plc, a Dublin-based pharmaceutical company, for an amount of $63 billion. With Allergan’s diversified product portfolio, AbbVie Inc.is expected to strengthen the company’s position in international biopharmaceutical markets. AbbVie Inc. invested in neuroscience, multiple sclerosis, Alzheimer’s disease, and investigating potential disease for Parkinson’s disease. Allergan plc is a pharmaceutical company engaged in developing, manufacturing, and commercializing branded pharmaceutical, biologic, surgical, device, and regenerative medicine products for patients worldwide.

Major players in the global anti-Parkinson drugs market are GlaxoSmithKline plc, Pfizer, Merck, Novartis, Roche, UCB S.A, Teva Pharmaceuticals, AbbVie Inc., Mylan, Boehringer Ingelheim, Orion Pharma, ACADIA Pharmaceuticals Inc, Sun Pharma, Wockhardt, Dr. Reddy’s, Intas, US WorldMeds, Zydus Cadila, Cipla, Strides, 1 A Pharma, Upsher-Smith, Lundbeck, Vertical Pharmaceuticals, LLC, Zambon Pharmaceuticals, M Somerset Pharmaceuticals Inc., and Wockhardt.

North America was the largest region in the anti-Parkinson drugs market in 2021. The Middle East is expected to be the fastest growing region in the global anti-Parkinson's market during the forecast period. The regions covered in the global anti-Parkinson drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the anti-Parkinson drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.

The global anti-Parkinson's drug market is segmented -

1) By Drugs Class: Levodopa/Carbidopa, Dopamine Receptor Agonists, Monoamine Oxidase Type B (MAO-B) Inhibitors, Catechol-O-Methyltransferase (COMT)-inhibitors, Anticholinergics, Others

2) By Route of Administration: Oral, Injection, Transdermal

3) By Distribution Channel: Hospital Pharmacies, Retailer Pharmacies, Online Pharmacies

    Table Of Contents

    1. Executive Summary

    2. Anti-Parkinson Drugs Market Characteristics

    3. Anti-Parkinson Drugs Market Trends And Strategies

    4. Impact Of COVID-19 On Anti-Parkinson Drugs

    5. Anti-Parkinson Drugs Market Size And Growth

    5.1. Global Anti-Parkinson Drugs Historic Market, 2016-2021, $ Billion

    5.1.1. Drivers Of The Market

    5.1.2. Restraints On The Market

    5.2. Global Anti-Parkinson Drugs Forecast Market, 2021-2026F, 2031F, $ Billion

    5.2.1. Drivers Of The Market

    5.2.2. Restraints On the Market

    6. Anti-Parkinson Drugs Market Segmentation

    6.1. Global Anti-Parkinson Drugs Market, Segmentation  By Drugs Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    Levodopa/Carbidopa

    Dopamine Receptor Agonists

    Monoamine Oxidase Type B (MAO-B) Inhibitors

    Catechol-O-Methyltransferase (COMT)-inhibitors

    Anticholinergics

    Other Drugs

    6.2. Global Anti-Parkinson Drugs Market, Segmentation   By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

     Oral

    Injection

    Transdermal

    6.3. Global Anti-Parkinson Drugs Market, Segmentation   By Distribution Channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    Hospital Pharmacies

    Retailer Pharmacies

    Online Pharmacies  

    7. Anti-Parkinson Drugs Market Regional And Country Analysis

    7.1. Global Anti-Parkinson Drugs Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    7.2. Global Anti-Parkinson Drugs Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    8. Asia-Pacific Anti-Parkinson Drugs Market  

    8.1. Asia-Pacific Anti-Parkinson Drugs Market Overview  

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    8.3. Asia-Pacific Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    9. China Anti-Parkinson Drugs Market  

    9.1. China Anti-Parkinson Drugs Market Overview  

    9.2. China Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion

    9.3. China Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion

    10. India Anti-Parkinson Drugs Market  

    10.1. India Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    10.2. India Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    11. Japan Anti-Parkinson Drugs Market  

    11.1. Japan Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    11.2. Japan Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    12. Australia Anti-Parkinson Drugs Market  

    12.1. Australia Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    12.2. Australia Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    13. Indonesia Anti-Parkinson Drugs Market  

    13.1. Indonesia Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    13.2. Indonesia Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    14. South Korea Anti-Parkinson Drugs Market  

    14.1. South Korea Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    14.2. South Korea Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    15. Western Europe Anti-Parkinson Drugs Market  

    15.1. Western Europe Anti-Parkinson Drugs Market Overview

    15.2. Western Europe Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    15.3. Western Europe Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    16. UK Anti-Parkinson Drugs Market  

    16.1. UK Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    16.2. UK Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    17. Germany Anti-Parkinson Drugs Market  

    17.1. Germany Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    17.2. Germany Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    18. France Anti-Parkinson Drugs Market  

    18.4. France Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    18.5. France Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    19. Eastern Europe Anti-Parkinson Drugs Market  

    19.1. Eastern Europe Anti-Parkinson Drugs Market Overview

    19.2. Eastern Europe Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    19.3. Eastern Europe Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    20. Russia Anti-Parkinson Drugs Market  

    20.1. Russia Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    20.2. Russia Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    21. North America Anti-Parkinson Drugs Market  

    21.1. North America Anti-Parkinson Drugs Market Overview

    21.2. North America Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    21.3. North America Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    22. USA Anti-Parkinson Drugs Market  

    22.1. USA Anti-Parkinson Drugs Market Overview

    22.2. USA Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    22.3. USA Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    23. South America Anti-Parkinson Drugs Market  

    23.1. South America Anti-Parkinson Drugs Market Overview

    23.2. South America Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    23.3. South America Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    24. Brazil Anti-Parkinson Drugs Market  

    24.1. Brazil Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    24.2. Brazil Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    25. Middle East Anti-Parkinson Drugs Market  

    25.1. Middle East Anti-Parkinson Drugs Market Overview

    25.2. Middle East Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    25.3. Middle East Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    26. Africa Anti-Parkinson Drugs Market  

    26.1. Africa Anti-Parkinson Drugs Market Overview

    26.2. Africa Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    26.3. Africa Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    27. Anti-Parkinson Drugs Market Competitive Landscape And Company Profiles

    27.1. Anti-Parkinson Drugs Market Competitive Landscape

    27.2. Anti-Parkinson Drugs Market Company Profiles

    27.2.1. GlaxoSmithKline plc

    27.2.1.1. Overview

    27.2.1.2. Products and Services

    27.2.1.3. Strategy

    27.2.1.4. Financial Performance

    27.2.2. Pfizer

    27.2.2.1. Overview

    27.2.2.2. Products and Services

    27.2.2.3. Strategy

    27.2.2.4. Financial Performance

    27.2.3. Merck

    27.2.3.1. Overview

    27.2.3.2. Products and Services

    27.2.3.3. Strategy

    27.2.3.4. Financial Performance

    27.2.4. Novartis

    27.2.4.1. Overview

    27.2.4.2. Products and Services

    27.2.4.3. Strategy

    27.2.4.4. Financial Performance

    27.2.5. Roche

    27.2.5.1. Overview

    27.2.5.2. Products and Services

    27.2.5.3. Strategy

    27.2.5.4. Financial Performance

    28. Anti-Parkinson Drugs Pipeline Analysis

    29. Key Mergers And Acquisitions In The Anti-Parkinson Drugs Market

    30. Anti-Parkinson Drugs Market Future Outlook and Potential Analysis

    31. Appendix

    31.1. Abbreviations

    31.2. Currencies

    31.3. Research Inquiries

    31.4. The Business Research Company

    31.5. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2016-2021, $ Billion
  • Table 2: Global Forecast Market Growth, 2021-2026F, 2031F, $ Billion
  • Table 3: Global Anti-Parkinson Drugs Market, Segmentation  By Drugs Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 4: Global Anti-Parkinson Drugs Market, Segmentation   By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 5: Global Anti-Parkinson Drugs Market, Segmentation   By Distribution Channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 6: Global Anti-Parkinson Drugs Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 7: Global Anti-Parkinson Drugs Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 8: Asia-Pacific, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 9: Asia-Pacific, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 10: China, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 11: China, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 12: India, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 13: India, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 14: Japan, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 15: Japan, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 16: Australia, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 17: Australia, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 18: Indonesia, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 19: Indonesia, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 20: South Korea, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 21: South Korea, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 22: Western Europe, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 23: Western Europe, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 24: UK, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 25: UK, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 26: Germany, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 27: Germany, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 28: France, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 29: France, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 30: Eastern Europe, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 31: Eastern Europe, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 32: Russia, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 33: Russia, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 34: North America, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 35: North America, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 36: USA, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 37: USA, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 38: South America, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 39: South America, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 40: Brazil, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 41: Brazil, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 42: Middle East, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 43: Middle East, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 44: Africa, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 45: Africa, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 46: GlaxoSmithKline plc Financial Performance
  • Table 47: Pfizer Financial Performance
  • Table 48: Merck Financial Performance
  • Table 49: Novartis Financial Performance
  • Table 50: Roche Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2016-2021, $ Billion
  • Figure 2: Global Forecast Market Growth, 2021-2026F, 2031F, $ Billion
  • Figure 3: Global Anti-Parkinson Drugs Market, Segmentation  By Drugs Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 4: Global Anti-Parkinson Drugs Market, Segmentation   By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 5: Global Anti-Parkinson Drugs Market, Segmentation   By Distribution Channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 6: Global Anti-Parkinson Drugs Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 7: Global Anti-Parkinson Drugs Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 8: Asia-Pacific, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 9: Asia-Pacific, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 10: China, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 11: China, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 12: India, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 13: India, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 14: Japan, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 15: Japan, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 16: Australia, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 17: Australia, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 18: Indonesia, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 19: Indonesia, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 20: South Korea, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 21: South Korea, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 22: Western Europe, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 23: Western Europe, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 24: UK, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 25: UK, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 26: Germany, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 27: Germany, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 28: France, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 29: France, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 30: Eastern Europe, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 31: Eastern Europe, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 32: Russia, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 33: Russia, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 34: North America, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 35: North America, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 36: USA, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 37: USA, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 38: South America, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 39: South America, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 40: Brazil, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 41: Brazil, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 42: Middle East, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 43: Middle East, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 44: Africa, Anti-Parkinson Drugs Market, Segmentation By Drugs Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 45: Africa, Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 46: GlaxoSmithKline plc Financial Performance
  • Figure 47: Pfizer Financial Performance
  • Figure 48: Merck Financial Performance
  • Figure 49: Novartis Financial Performance
  • Figure 50: Roche Financial Performance
Global Anti-Infective Drugs Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Cell and Gene Therapy Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Pharmaceutical Drugs And Biologics Logistics Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Pharmaceutical Drugs Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Microbiome Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global G-CSF (Granulocyte Colony Stimulating Factors) Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Therapeutic Proteins Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Neurology Devices Global Market Report 2022 – By Type (Cerebrospinal Fluid Management (CSF) Devices And Equipment, Interventional Neurology Devices And Equipment, Neurosurgery Devices And Equipment, Neurostimulation Devices), By End User (Hospitals And Clinics, Diagnostic Laboratories), By Type of Expenditure (Public, Private), By Product (Instruments/Equipment, Disposables) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Antisense And RNAi Therapeutics Market 2021- By Technology (RNA Interference, Antisense RNA), By Route Of Administration (Intravenous injections, Intra Dermal injunctions, Other delivery methods), By Indication (Oncology, Cardiovascular device, Respiratory disorders, Neurological disorders, Infectious disease), And By Region, Opportunities And Strategies – Global Forecast To 2030
View Report
Neurophysiology Devices And Equipment Global Market Report 2022 – By Technology (Electromyography (EMG), Electroencephalography (EEG), Electrocorticography (ECoG), Evoked potential (EP)), By End Users (Hospitals, Ambulatory Surgical Centers), By Modality (Standalone, Portable) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Neurostimulation Devices Global Market Report 2022 – By Product (Implantable Devices, External Devices), By Application (Pain Management, Epilepsy, Essential Tremor, Urinary and Fecal Incontinence, Depression, Dystonia, Gastroparesis, Parkinson's Disease), By End User (Hospitals, Rehabilitation Centers, Medical Clinic), By Implantable Devices (Cochlear Implants, Deep Brain Stimulation, Spinal Cord Stimulation, Vagus Nerve Stimulation, Sacral Nerve Stimulation, Gastric Electric Stimulation), By External Devices (Transcranial Magnetic Stimulation (TMS), Transcutaneous Electrical Nerve Stimulation (TENS)) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Neurosurgery Devices And Equipment Global Market Report 2022 – By Device Type (Neuroendoscope, Stereotactic Systems, Aneurysm Clips, Neurostimulation Devices, Cerebrospinal Fluid Management Devices, Neurosurgical Evacuation Device, Neurosurgical Navigation Systems, Neurosurgery Surgical Power Tools, Others(Ultrasonic Aspirators, Surgical Instruments)), By Surgery Type (Intracranial Surgery, Endonasal Neurosurgery, Spinal Surgery), By End User (Hospitals, Ambulatory Surgical Centers) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Antiemetics And Antinauseants Global Market Report 2022 – By Drug (Dopamine antagonists, NK1 receptor antagonist, Antihistamines (H1 histamine receptor antagonists), Cannabinoids, Benzodiazepines, Anticholinergics, Steroids, 5-HT3 receptor antagonists, Others), By Application (Chemotherapy, Motion sickness, Gastroenteritis, General anaesthetics, Opioid analgesics, Dizziness, Pregnancy, Food poisoning, Emotional stress, Others), By End Users (Hospital, Medical Center, Clinic, Research Institutes) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Central Nervous System Drugs Global Market Report 2022 – By Type (Analgesics, Anti-Parkinson Drugs, Anesthetics, Anti-Epileptics), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores), By Route Of Administration (Oral, Parenteral), By Drug Classification (Branded Drugs, Generic Drugs), By Mode Of Purchase (Prescription-Based Drugs, Over-The-Counter Drugs) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Neurodegenerative Disorder Therapeutics Global Market Report 2022 – By Indication Type (Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis, Huntington Disease, Other Indication Types), By Drug Type (N- methyl- D- aspartate Receptor, Selective Serotonin Reuptake Inhibitor, Dopamine Inhibitors, Other Drug Types), By Distribution (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) – Market Size, Trends, And Global Forecast 2022-2026
View Report

Call Us

+1 3156230293

(Americas)

+44 2071930708

(Europe)

+91 8897263534

(Asia & Others)